BPG is committed to discovery and dissemination of knowledge
Articles Published Processes Featured Articles Journals Submit a Manuscript
Cited by in CrossRef
For: Ponziani FR, Zocco MA, D’Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol 2017; 23(25): 4491-4499 [PMID: 28740337 DOI: 10.3748/wjg.v23.i25.4491]
URL: https://www.wjgnet.com/1007-9327/full/v23/i25/4491.htm
(314) (327) (0) (0) (14531) (137)
Number Citing Articles
1
Francesca Romana Ponziani, Gaetano Coppola, Pierluigi Rio, Mario Caldarelli, Raffaele Borriello, Giovanni Gambassi, Antonio Gasbarrini, Rossella Cianci. Factors Influencing Microbiota in Modulating Vaccine Immune Response: A Long Way to Go. Vaccines 2023; 11(10) doi: 10.3390/vaccines11101609
2
Shivam Kalia, Preetam Nath, Anil Chandra Anand, Shivam Gupta, Abhishek Verma, Bipadabhanjan Mallick, Dibyalochan Praharaj, Sarat Chandra Panigrahi, Saroj Kanta Sahu, Suprabhat Giri, Subrat Kumar Acharya. Effect of oral rifaximin for prevention of infected pancreatic necrosis and mortality in severe acute pancreatitis: An open-label randomized controlled trial. Pancreatology 2025; 25(7) doi: 10.1016/j.pan.2025.09.009
3
Herbert L. DuPont, Graeme N. Forrest. The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review. Clinical Microbiology Reviews 2023; 36(4) doi: 10.1128/cmr.00039-23
4
Hidenori OHKUBO, Takaomi KESSOKU, Kosuke TANAKA, Kota TAKAHASHI, Tomohiro TAKATSU, Tsutomu YOSHIHARA, Noboru MISAWA, Keiichi ASHIKARI, Akiko FUYUKI, Shingo KATO, Takuma HIGURASHI, Kunihiro HOSONO, Masato YONEDA, Toshihiro MISUMI, Satoru SHINODA, Vincenzo STANGHELLINI, Atsushi NAKAJIMA. Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II—a exploratory trial. Bioscience of Microbiota, Food and Health 2024; 43(2) doi: 10.12938/bmfh.2023-080
5
Jonel Trebicka, Jane Macnaughtan, Bernd Schnabl, Debbie L. Shawcross, Jasmohan S. Bajaj. The microbiota in cirrhosis and its role in hepatic decompensation. Journal of Hepatology 2021; 75 doi: 10.1016/j.jhep.2020.11.013
6
Marina Fortea, Mercé Albert-Bayo, Mar Abril-Gil, John-Peter Ganda Mall, Xavier Serra-Ruiz, Alejandro Henao-Paez, Elba Expósito, Ana María González-Castro, Danila Guagnozzi, Beatriz Lobo, Carmen Alonso-Cotoner, Javier Santos. Present and Future Therapeutic Approaches to Barrier Dysfunction. Frontiers in Nutrition 2021; 8 doi: 10.3389/fnut.2021.718093
7
Rooshi Nathwani, Benjamin Mullish, David Kockerling, Alexander Cole, Nowlan Selvapatt, Ameet Dhar. Review of Rifaximin: A Summary of the Current Evidence and Benefits Beyond Licensed Use. European Medical Journal 2021;  doi: 10.33590/emj/21-00026
8
Marta Maestri, Francesco Santopaolo, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani. Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1110536
9
Debjani Ray, Piyas Bose, Saptarshi Mukherjee, Subhadeep Roy, Santanu Kaity. Recent drug delivery systems targeting the gut-brain-microbiome axis for the management of chronic diseases. International Journal of Pharmaceutics 2025; 680 doi: 10.1016/j.ijpharm.2025.125776
10
Ayodeji Awoyemi, Cristiane Mayerhofer, Alex S. Felix, Johannes R. Hov, Samuel D. Moscavitch, Knut Tore Lappegård, Anders Hovland, Sigrun Halvorsen, Bente Halvorsen, Ida Gregersen, Asbjørn Svardal, Rolf K. Berge, Simen H. Hansen, Alexandra Götz, Kristian Holm, Pål Aukrust, Sissel Åkra, Ingebjørg Seljeflot, Svein Solheim, Andrea Lorenzo, Lars Gullestad, Marius Trøseid, Kaspar Broch. Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine 2021; 70 doi: 10.1016/j.ebiom.2021.103511
11
Vladimir Ivashkin, Oleg Shifrin, Roman Maslennikov, Elena Poluektova, Alexander Korolev, Anna Kudryavtseva, George Krasnov, Nona Benuni, Giovanni Barbara. Eubiotic effect of rifaximin is associated with decreasing abdominal pain in symptomatic uncomplicated diverticular disease: results from an observational cohort study. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02690-x
12
Aneta Nowicka, Hanna Tomczak, Edyta Szałek, Agnieszka Karbownik, Lidia Gil. Microbial Crosstalk with Therapy: Pharmacomicrobiomics in AML—One Step Closer to Personalized Medicine. Biomedicines 2025; 13(7) doi: 10.3390/biomedicines13071761
13
Xiaojun Zhuang, Zhenyi Tian, Mei Luo, Lishou Xiong. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome. BMC Gastroenterology 2020; 20(1) doi: 10.1186/s12876-020-01336-6
14
Nahum Mendez-Sanchez, Carlos Esteban Coronel-Castillo, Jacqueline Cordova-Gallardo, Xingshun Qi. Antibiotics in Chronic Liver Disease and Their Effects on Gut Microbiota. Antibiotics 2023; 12(10) doi: 10.3390/antibiotics12101475
15
M. Fidelle, L. Derosa, B. Routy, L. Zitvogel. Contourner la résistance à l’immunothérapie des cancers : interventions centrées sur le microbiome intestinal. Bulletin de l'Académie Nationale de Médecine 2021; 205(4) doi: 10.1016/j.banm.2021.01.022
16
Francesco Santopaolo, Gaetano Coppola, Lucia Giuli, Antonio Gasbarrini, Francesca Romana Ponziani. Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management. Microbiology Research 2022; 13(3) doi: 10.3390/microbiolres13030038
17
Lucia Redondo-Cuevas, Lucia Belloch, Vanesa Martín-Carbonell, Angela Nicolás, Iulia Alexandra, Laura Sanchis, Marina Ynfante, Michel Colmenares, María Mora, Ana Reyes Liebana, Beatriz Antequera, Francisco Grau, José Ramón Molés, Rubén Cuesta, Samuel Díaz, Noelia Sancho, Héctor Tomás, José Gonzalvo, Mercedes Jaén, Eva Sánchez, Ana Garayoa, Nadia Moreno, Ana Gallén, Ernesto Cortés-Castell, Xavier Cortés-Rizo. Do Herbal Supplements and Probiotics Complement Antibiotics and Diet in the Management of SIBO? A Randomized Clinical Trial. Nutrients 2024; 16(7) doi: 10.3390/nu16071083
18
Vasile Valeriu Lupu, Anca Adam Raileanu, Cristina Maria Mihai, Ionela Daniela Morariu, Ancuta Lupu, Iuliana Magdalena Starcea, Otilia Elena Frasinariu, Adriana Mocanu, Felicia Dragan, Silvia Fotea. The Implication of the Gut Microbiome in Heart Failure. Cells 2023; 12(8) doi: 10.3390/cells12081158
19
E. V. Golovanova. Cyclic rifaximin and soluble dietary fiber therapy for symptomatic diverticular disease: effective prevention of complications. Medical Council 2019; (3) doi: 10.21518/2079-701X-2019-3-98-107
20
Tilman Sauerbruch, Martin Hennenberg, Jonel Trebicka, Ulrich Beuers. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.718783
21
Puru Rattan, Carlos D. Minacapelli, Vinod Rustgi. The Microbiome and Hepatocellular Carcinoma. Liver Transplantation 2020; 26(10) doi: 10.1002/lt.25828
22
Connor Stewart, Tim Jang, George Mo, Nader Mohamed, Maria Poplawska, Ogechukwu Egini, Dibyendu Dutta, Seah H. Lim. Antibiotics to modify sickle cell disease vaso-occlusive crisis?. Blood Reviews 2021; 50 doi: 10.1016/j.blre.2021.100867
23
Shiv K. Sarin, Apurva Pande, Bernd Schnabl. Microbiome as a therapeutic target in alcohol-related liver disease. Journal of Hepatology 2019; 70(2) doi: 10.1016/j.jhep.2018.10.019
24
Georgia Brown, Emily C. Hoedt, Simon Keely, Ayesha Shah, Marjorie M. Walker, Gerald Holtmann, Nicholas J. Talley. Role of the duodenal microbiota in functional dyspepsia. Neurogastroenterology & Motility 2022; 34(11) doi: 10.1111/nmo.14372
25
Yuyuan Hu, Yan Li, Qiang Zhang, Qiaobo Tan, Haoze Liu, Yuhang Yang, Chenfei Jin, Wei Zhang, Jinghan Jia, Jinxi Wang. The AMP–antibiotic–microbiota triad in IBD: a mechanistic framework for dysregulated antimicrobial defense. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1779550
26
Mi-Young Kim, Sang-Woon Choi. Dietary modulation of gut microbiota for the relief of irritable bowel syndrome. Nutrition Research and Practice 2021; 15(4) doi: 10.4162/nrp.2021.15.4.411
27
O. M. Drapkina, L. B. Lazebnik, I. G. Bakulin, E. V. Skazyvaeva, N. V. Bakulina, S. I. Sitkin, M. I. Skalinskaya, M. S. Zhuravleva, E. B. Avalueva, M. A. Livzan, D. S. Bordin, A. I. Khavkin. Colonic diverticular disease: clinical presentation, diagnosis, treatment, and prevention Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine, the Gastroenterological Scientific Society of Russia, and the North- West Society of Gastroenterologists and Hepatologists. Experimental and Clinical Gastroenterology 2023; (2) doi: 10.31146/1682-8658-ecg-210-2-33-69
28
Sharlize Pedroza Matute, Sasitaran Iyavoo. Exploring the gut microbiota: lifestyle choices, disease associations, and personal genomics. Frontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1225120
29
Aylin Deljavan Ghodrati, Tansel Comoglu. Rifaximin and alternative agents in the management of irritable bowel syndrome: A comprehensive review. Archiv der Pharmazie 2024; 357(10) doi: 10.1002/ardp.202400356
30
Joshua Henrina, Irvan Cahyadi, Hoo Felicia Hadi Gunawan, Leonardo Paskah Suciadi. Gut Microbiota as a Potential Treatment Target in Patient with Chronic Heart Failure. SN Comprehensive Clinical Medicine 2020; 2(9) doi: 10.1007/s42399-020-00436-4
31
Takaomi Kessoku, Takashi Kobayashi, Kento Imajo, Kosuke Tanaka, Atsushi Yamamoto, Kota Takahashi, Yuki Kasai, Anna Ozaki, Michihiro Iwaki, Asako Nogami, Yasushi Honda, Yuji Ogawa, Shingo Kato, Takuma Higurashi, Kunihiro Hosono, Masato Yoneda, Takayuki Okamoto, Haruki Usuda, Koichiro Wada, Noritoshi Kobayashi, Satoru Saito, Atsushi Nakajima. Endotoxins and Non-Alcoholic Fatty Liver Disease. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.770986
32
Daniela Campion, Ilaria Giovo, Paola Ponzo, Giorgio M Saracco, Federico Balzola, Carlo Alessandria. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World Journal of Hepatology 2019; 11(6): 489-512 doi: 10.4254/wjh.v11.i6.489
33
Oleg V. Golovenko, Alexey O. Golovenko. Opinions of gastroenterologists about intestinal microbiota modulating agents: results of the survey in focus groups. Consilium Medicum 2023; 25(5) doi: 10.26442/20751753.2023.5.202250
34
Beatriz Sanchez-Jimenez, Norberto C Chavez-Tapia, Janus C Jakobsen, Dimitrinka Nikolova, Christian Gluud. Antibiotic prophylaxis for people with cirrhosis and variceal bleeding. Cochrane Database of Systematic Reviews 2018;  doi: 10.1002/14651858.CD013214
35
Lucia Giuli, Marta Maestri, Francesco Santopaolo, Maurizio Pompili, Francesca Romana Ponziani. Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease. Metabolites 2023; 13(6) doi: 10.3390/metabo13060772
36
Qiujin Jia, Hao Li, Huan Zhou, Xiaonan Zhang, Ao Zhang, Yingyu Xie, Yanyang Li, Shichao Lv, Junping Zhang. Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure. Cardiovascular Therapeutics 2019; 2019 doi: 10.1155/2019/5164298
37
Lamiaa A. Ahmed, Khaled F. Al-Massri. Insights into the role of gut microbiota modulation in the management of various cardiovascular diseases: A new approach for improving the efficacy of current cardiovascular medications. European Journal of Pharmacology 2025; 1007 doi: 10.1016/j.ejphar.2025.178210
38
Hanzhi Xu, Xun Qiu, Zhoucheng Wang, Kai Wang, Yawen Tan, Fengqiang Gao, Marcos Vinicius Perini, Xiao Xu. Role of the portal system in liver regeneration: From molecular mechanisms to clinical management. Liver Research 2024; 8(1) doi: 10.1016/j.livres.2024.01.002
39
Barbara Skrzydło-Radomańska, Bożena Cukrowska. How to Recognize and Treat Small Intestinal Bacterial Overgrowth?. Journal of Clinical Medicine 2022; 11(20) doi: 10.3390/jcm11206017
40
Giovanni Marasco, Francesco Buttitta, Cesare Cremon, Maria Raffaella Barbaro, Vincenzo Stanghellini, Giovanni Barbara. The role of microbiota and its modulation in colonic diverticular disease. Neurogastroenterology & Motility 2023; 35(12) doi: 10.1111/nmo.14615
41
Iqra Usman, Aamir Anwar, Shivang Shukla, Priya Pathak. Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases. Cardiovascular & Hematological Disorders-Drug Targets 2024; 24(1) doi: 10.2174/011871529X310857240607103028
42
Yafei Chen, Zuoyi Jiang, Zhihai Lei, Jihui Ping, Juan Su. Effect of rifaximin on gut-lung axis in mice infected with influenza A virus. Comparative Immunology, Microbiology and Infectious Diseases 2021; 75 doi: 10.1016/j.cimid.2021.101611
43
Emma Bruder, Olivier Espéli. Escherichia coli bacteria associated with Crohn’s disease persist within phagolysosomes. Current Opinion in Microbiology 2022; 70 doi: 10.1016/j.mib.2022.102206
44
Carmen Correale, Martina Morandi, Antonio Gil-Gomez, Alessandra Silvestri, Andrea Gatti, Daniele Braga, Annalisa Maroli, Caterina Foppa, Stefano De Zanet, Francesca Algieri, Michela Lizier, Riccardo Rossetti, Sara Carloni, Giuseppe Penna, Antonino Spinelli, Paola Brescia, Maria Rescigno. Muribaculum as a microbial contributor of rifaximin-induced mucosal protection during chemotherapy. Gut Microbes 2026; 18(1) doi: 10.1080/19490976.2026.2685994
45
Svenja Nolte, Karsten Krüger, Claudia Lenz, Karen Zentgraf. Optimizing the Gut Microbiota for Individualized Performance Development in Elite Athletes. Biology 2023; 12(12) doi: 10.3390/biology12121491
46
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2019; 51(2) doi: 10.1016/j.dld.2018.11.035
47
Parna Pathak, Arup Choudhury. Journal Summary: Do Antibiotics Predispose to the Development of Inflammatory Bowel Disease?. Journal of Gastrointestinal Infections 2024; 14(01) doi: 10.1055/s-0044-1788549
48
Shaan Mody, Alison Laxer, Jermie Gandhi. Small Intestinal Bacterial Overgrowth in the Pediatric Population: A Review of Pathophysiology, Diagnosis, and Management. Current Gastroenterology Reports 2026; 28(1) doi: 10.1007/s11894-026-01059-w
49
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. World Journal of Gastroenterology 2020; 26(16): 1901-1911 doi: 10.3748/wjg.v26.i16.1901
50
Donglei Sun, Chao Zuo, Wei Huang, Jingjing Wang, Zunzhen Zhang. Triclosan targeting of gut microbiome ameliorates hepatic steatosis in high fat diet-fed mice. The Journal of Antibiotics 2022; 75(6) doi: 10.1038/s41429-022-00522-w
51
Brian Bicknell, Ann Liebert, Thomas Borody, Geoffrey Herkes, Craig McLachlan, Hosen Kiat. Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome. International Journal of Molecular Sciences 2023; 24(11) doi: 10.3390/ijms24119577
52
Haiming Hu, Aizhen Lin, Mingwang Kong, Xiaowei Yao, Mingzhu Yin, Hui Xia, Jun Ma, Hongtao Liu. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. Journal of Gastroenterology 2020; 55(2) doi: 10.1007/s00535-019-01649-8
53
Federica Di Vincenzo, Alberto Nicoletti, Marcantonio Negri, Federica Vitale, Lorenzo Zileri Dal Verme, Antonio Gasbarrini, Francesca Romana Ponziani, Lucia Cerrito. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics 2023; 12(6) doi: 10.3390/antibiotics12061068
54
Aleksandra Blonska, Marcin Chojnacki, Anna Macieja, Janusz Blasiak, Ireneusz Majsterek, Jan Chojnacki, Tomasz Poplawski. Tryptophan Metabolism in Postmenopausal Women with Functional Constipation. International Journal of Molecular Sciences 2023; 25(1) doi: 10.3390/ijms25010273
55
O. S. Shifrin, E. A. Poluektova, A. V. Korolev, T. I. Semenova, M. V. Shein, G. N. Leksikova, O. A. Tokareva, O. E. Davydova, P. S. Andreev, S. E. Katorkin, A. A. Chernov, A. V. Zhuravlev, O. S. Sek, A. A. Kopina, N. Yu. Samokhina, Yu. V. Gorozhankina, M. F. Samigullin, V. S. Groshilin, E. N. Borisova, T. A. Petrova, I. Yu. Pirogova, S. V. Mednikov, N. V. Smagin, A. S. Sarsenbaeva, N. V. Smirnova, L. G. Kirsanova, N. M. Malyutina, M. A. Smirnova, E. N. Shleikova, V. T. Ivashkin. Russian Non-Interventional Study of the Efficacy and Tolerability of Rifaximin-α Therapy in Patients with Uncomplicated Diverticular Disease under the Conditions of Outpatient Practice. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2020; 30(1) doi: 10.22416/1382-4376-2020-30-1-14-25
56
E. Yu. Plotnikova. Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. Meditsinskiy sovet = Medical Council 2021; (5) doi: 10.21518/2079-701X-2021-5-167-174
57
Danica Bajic, Adrian Niemann, Anna-Katharina Hillmer, Raquel Mejias-Luque, Sena Bluemel, Melissa Docampo, Maja C Funk, Elena Tonin, Michael Boutros, Bernd Schnabl, Dirk H Busch, Tsuyoshi Miki, Roland M Schmid, Marcel R M van den Brink, Markus Gerhard, Christoph K Stein-Thoeringer. Gut Microbiota-Derived Propionate Regulates the Expression of Reg3 Mucosal Lectins and Ameliorates Experimental Colitis in Mice. Journal of Crohn's and Colitis 2020; 14(10) doi: 10.1093/ecco-jcc/jjaa065
58
Aleksandra Bołdys, Łukasz Bułdak, Mateusz Maligłówka, Stanisław Surma, Bogusław Okopień. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease. Medicina 2023; 59(10) doi: 10.3390/medicina59101789
59
Carmelo Scarpignato, Neil Stollman. Colonic Diverticular Disease. 2022;  doi: 10.1007/978-3-030-93761-4_18
60
Elina Manzhalii, Valentyna Moyseyenko, Vitalii Kondratiuk, Nataliia Molochek, Tetyana Falalyeyeva, Nazarii Kobyliak. Effect of a specific <i>Escherichia coli Nissle 1917</i> strain on minimal/mild hepatic encephalopathy treatment. World Journal of Hepatology 2022; 14(3): 634-646 doi: 10.4254/wjh.v14.i3.634
61
Domenico Ferro, Francesco Baratta, Daniele Pastori, Nicholas Cocomello, Alessandra Colantoni, Francesco Angelico, Maria Del Ben. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020; 12(9) doi: 10.3390/nu12092762
62
Ștefan-Sorin Aramă. Irritable bowel syndrome and probiotics place in therapeutic strategies. Infectio.ro 2018; (1) doi: 10.26416/Inf.56.4.2018.2188
63
Daniele Zama, Gianluca Bossù, Davide Leardini, Edoardo Muratore, Elena Biagi, Arcangelo Prete, Andrea Pession, Riccardo Masetti. Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation. Therapeutic Advances in Hematology 2020; 11 doi: 10.1177/2040620719896961
64
Cristina Tocia, Irina Magdalena Dumitru, Luana Alexandrescu, Lucian Cristian Petcu, Eugen Dumitru. Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?. Medicine 2021; 100(1) doi: 10.1097/MD.0000000000024059
65
Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan, Zhongxing Jiang. Applications of gut microbiota in patients with hematopoietic stem-cell transplantation. Experimental Hematology & Oncology 2020; 9(1) doi: 10.1186/s40164-020-00194-y
66
Vikram Mahajan, Suman Singh, Priyanka Thakur, Amisha Kukreja, Rohit Negi. Severe Sunburn-Like Adverse Cutaneous Drug Reaction in a Patient on Treatment with Rifaximin: A Rare Case of Acute Phototoxic Drug Reaction. EMJ Dermatology 2022;  doi: 10.33590/emjdermatol/21-00233
67
Shan Jiang, Xiaolu Wei, Hongjie Wang, Yanyan Zhou, Lihua Chen, Lianmei Wang, Feng Wang, Qilong Wu, Nan Si, Baolin Bian, Haiyu Zhao. Biotransformed bear bile powder alleviates diet-induced nonalcoholic fatty liver disease in mice by regulating the gut microbiota and reversing lipid metabolism. Arabian Journal of Chemistry 2024; 17(2) doi: 10.1016/j.arabjc.2023.105578
68
Fulvio Pandico, Anna Citarella, Simona Cammarota, Francesca Futura Bernardi, Ernesto Claar, Carmine Coppola, Marianna Cozzolino, Federica De Rosa, Massimo Di Gennaro, Marianna Fogliasecca, Roberta Giordana, Daniela Pacella, Alessandro Russo, Vito Salerno, Luca Scafa, Ugo Trama. Rifaximin Use, Adherence and Persistence in Patients with Hepatic Encephalopathy: A Real-World Study in the South of Italy. Journal of Clinical Medicine 2023; 12(13) doi: 10.3390/jcm12134515
69
Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World Journal of Gastroenterology 2020; 26(2): 199-218 doi: 10.3748/wjg.v26.i2.199
70
Aikaterini Mastoraki, Dimitrios Schizas, Athina Tousia, George Chatzopoulos, Anastasia Gkiala, Athanasios Syllaios, Maximos Frountzas, Pantelis Vassiliu, Georgios E. Theodoropoulos, Evangelos Felekouras. Evaluation of molecular and genetic predisposing parameters at diverticular disease of the colon. International Journal of Colorectal Disease 2021; 36(5) doi: 10.1007/s00384-020-03812-7
71
Phillipp Hartmann, Bernd Schnabl. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease 2021; 41(01) doi: 10.1055/s-0040-1719174
72
S. Ghanem, C.J. Kim, D. Dutta, M. Salifu, S.H. Lim. Antimicrobial therapy during cancer treatment: Beyond antibacterial effects. Journal of Internal Medicine 2021; 290(1) doi: 10.1111/joim.13238
73
Buyun Qian, Kaiyu Zhang, Yuan Li, Kangyun Sun. Update on gut microbiota in cardiovascular diseases. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.1059349
74
E. A. Kashukh, E. A. Poluektova, A. V. Kudryavtseva, G. S. Krasnov, V. I. Kazey, P. D. Sobolev, P. V. Gremyakova, V. T. Ivashkin. Effect of Rifaximin and a Multi-Strain Probiotic on the Intestinal Microbiome and Cardiovascular Risk Indicators in Patients with Coronary Heart Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology 2019; 29(4) doi: 10.22416/1382-4376-2019-29-4-38-49
75
Aravind Thavamani, Senthilkumar Sankararaman, Hilmi Al-Shakhshir, Mauricio Retuerto, Sujithra Velayuthan, Thomas J. Sferra, Mahmoud Ghannoum. Impact of Erythromycin as a Prokinetic on the Gut Microbiome in Children with Feeding Intolerance—A Pilot Study. Antibiotics 2023; 12(11) doi: 10.3390/antibiotics12111606
76
Camila Fontoura Acosta Ribeiro, Gislaine Greice de Oliveira Silva Silveira, Elizabete de Souza Cândido, Marlon Henrique Cardoso, Cristiano Marcelo Espínola Carvalho, Octávio Luiz Franco. Effects of Antibiotic Treatment on Gut Microbiota and How to Overcome Its Negative Impacts on Human Health. ACS Infectious Diseases 2020; 6(10) doi: 10.1021/acsinfecdis.0c00036
77
Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński. Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis. Prospects in Pharmaceutical Sciences 2024; 22(2) doi: 10.56782/pps.196
78
WeiZhou Wang, YunTao Tang, ZiQian Wan, ZhiQuan Zhang, ZhouHang Zheng, HuiLong Liu, QiPeng Shu, ShangZe Li. Gut microbiota modulates nonalcoholic fatty liver disease (NAFLD) progression via regulation of gluconeogenesis: mechanisms and translational research. Pharmacological Research 2026; 233 doi: 10.1016/j.phrs.2026.108444
79
Xiao Hong, Shuo Huang, He Jiang, Qing Ma, Jiang Qiu, Qihan Luo, Chunlu Cao, Yiyang Xu, Fuzhe Chen, Yufan Chen, Chunfeng Sun, Haozhe Fu, Yiming Liu, Changyu Li, Fangming Chen, Ping Qiu. Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1432480
80
Cyriac Abby Philips, Philip Augustine, Karthik Ganesan, Shatakshi Ranade, Varun Chopra, Kunal Patil, Sonie Shende, Rizwan Ahamed, Sandeep Kumbar, Sasidharan Rajesh, Tom George, Meera Mohanan, Narain Mohan, Nikhil Phadke, Mridula Rani, Arjun Narayanan, Suchetha M. Jagan. The role of gut microbiota in clinical complications, disease severity, and treatment response in severe alcoholic hepatitis. Indian Journal of Gastroenterology 2022; 41(1) doi: 10.1007/s12664-021-01157-9
81
Sabine Becker, Louise B. Grode, Ole K. Bonderup. Rifaximin Treatment of Collagenous Colitis: A Randomised, Double-Blind, Placebo-Controlled Trial. Inflammatory Intestinal Diseases 2024; 9(1) doi: 10.1159/000536124
82
Maximos Frountzas, Victoria Michalopoulou, Georgia Georgiou, Despoina Kanata, Maria Matiatou, Despina Kimpizi, Georgia Matthaiou, Spilios Spiliotopoulos, Dimitrios Vouros, Konstantinos G. Toutouzas, George E. Theodoropoulos. The Impact of Mechanical Bowel Preparation and Oral Antibiotics in Colorectal Cancer Surgery (MECCA Study): A Prospective Randomized Clinical Trial. Journal of Clinical Medicine 2024; 13(4) doi: 10.3390/jcm13041162
83
Carlo Airola, Andrea Severino, Serena Porcari, William Fusco, Benjamin H. Mullish, Antonio Gasbarrini, Giovanni Cammarota, Francesca Romana Ponziani, Gianluca Ianiro. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy. Antibiotics 2023; 12(5) doi: 10.3390/antibiotics12050868
84
Gauri S Khatri, Christine Kurian, Asha Anand, Paari KA. Gut Homeostasis; Microbial Cross Talks in Health and Disease Management. Current Research in Nutrition and Food Science Journal 2021; 9(3) doi: 10.12944/CRNFSJ.9.3.28
85
Ishfaq Hassan Mir, Saqib Hassan, Joseph Selvin, Chinnasamy Thirunavukkarasu. Human Microbiome in Health, Disease, and Therapy. 2023;  doi: 10.1007/978-981-99-5114-7_7
86
An‐Tian Chen, Jian Zhang, Yuhui Zhang. Gut microbiota in heart failure and related interventions. iMeta 2023; 2(3) doi: 10.1002/imt2.125
87
Y. A. Sorokina, N. A. Petunina, S. D. Sinyushkina, A. V. Gorinova, M. I. Pryazhnikova, S. A. Sukhanov, A. S. Rudakov, O. V. Zanozina. Cardiovascular pathology and intestinal microbiome relationship: potential targets of pharmacotherapy. Meditsinskiy sovet = Medical Council 2023; 17(9) doi: 10.21518/ms2023-158
88
Gokhan Aydin, Bengisu Ulu Karasu, Selcuk Takir, Ahmet Cumhur Dulger. Impact of Rifaximin, a Gut-Selective Antibiotic, on Gastric Intestinal Metaplasia: A Retrospective Study. Journal of Clinical Medicine 2026; 15(13) doi: 10.3390/jcm15135282
89
Sarah Lechner, Matthew Yee, Berkeley N. Limketkai, Edward A. Pham. Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction. Digestive Diseases and Sciences 2020; 65(3) doi: 10.1007/s10620-020-06100-0
90
Jozef Kuzma, Dittmar Chmelař, Michal Hájek, Alexandra Lochmanová, Ivan Čižnár, Miroslav Rozložník, Miloslav Klugar. The role of intestinal microbiota in the pathogenesis of colorectal carcinoma. Folia Microbiologica 2020; 65(1) doi: 10.1007/s12223-019-00706-2
91
Irene Palenca, Silvia Basili Franzin, Marcella Pesce, Giovanni Sarnelli, Giuseppe Esposito. Rifaximin’s therapeutic spectrum: approved indications and experimental insights into emerging uses. Pharmacological Reports 2026; 78(3) doi: 10.1007/s43440-026-00830-0
92
Mohamed Tausif Siddiqui, Gail A.M. Cresci. Microbiota reprogramming for treatment of alcohol-related liver disease. Translational Research 2020; 226 doi: 10.1016/j.trsl.2020.07.004
93
Joanna Nycz, Alicja Zajdel. Mikrobiota jelitowa a leki. Interakcje wpływające na skuteczność i bezpieczeństwo farmakoterapii. Postępy Higieny i Medycyny Doświadczalnej 2021; 75(1) doi: 10.2478/ahem-2021-0009
94
Olga K. Didyk, Volodymyr V. Chernyavskyi, Vadym P. Shypulin, Victoriia V. Tishchenko. Effectiveness of rifaximin and probiotics for the correction of intestinal permeability in patients with metabolic-associated fatty liver disease in combination with type 2 diabetes mellitus. Wiadomości Lekarskie 2024; 77(4) doi: 10.36740/WLek202404118
95
Francesco Di Pierro, Marco Pane. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clinical Nutrition ESPEN 2021; 42 doi: 10.1016/j.clnesp.2020.12.025
96
Beatriz Sanchez-Jimenez, Norberto C Chavez-Tapia, Janus C Jakobsen, Dimitrinka Nikolova, Christian Gluud. Antibiotic prophylaxis versus placebo or no intervention for people with cirrhosis and variceal bleeding. Cochrane Database of Systematic Reviews 2018;  doi: 10.1002/14651858.CD013175
97
Yuanqing Zhu, Wenkang Gao, Mingjian Cheng, Xuyang li, Kailin Cai, Liuying Chen, Huikuan Chu. Harnessing the power of the gut microbiome: a review of supplementation diagnosis and therapy for liver cirrhosis. Cellular and Molecular Life Sciences 2026; 83(1) doi: 10.1007/s00018-026-06098-0
98
Yahkub Babatunde Mutalub, Monsurat Abdulwahab, Alkali Mohammed, Aishat Mutalib Yahkub, Sameer Badri AL-Mhanna, Wardah Yusof, Suk Peng Tang, Aida Hanum Ghulam Rasool, Siti Safiah Mokhtar. Gut Microbiota Modulation as a Novel Therapeutic Strategy in Cardiometabolic Diseases. Foods 2022; 11(17) doi: 10.3390/foods11172575
99
Brian E. Lacy, Patrick Gagnon-Sanschagrin, Zeev Heimanson, Rebecca Bungay, Remi Bellefleur, Annie Guérin, Brock Bumpass, Danellys Borroto, George Joseph, Ankur A. Dashputre. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea. Advances in Therapy 2024; 41(6) doi: 10.1007/s12325-024-02832-x
100
Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu. Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice. Frontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00044
101
Chengchen Yang, Yuli Song, Chengbo Yu. The Gut Microbiome in Liver Cirrhosis: Stage-Specific Alterations and Therapeutic Strategies. Infectious Microbes and Diseases 2026; 8(2) doi: 10.1097/IM9.0000000000000211
102
Peng Zhao, Suhong Zhao, Jinwei Tian, Xinxin Liu. Significance of Gut Microbiota and Short-Chain Fatty Acids in Heart Failure. Nutrients 2022; 14(18) doi: 10.3390/nu14183758
103
Marwa Salih ‎Al-Naimi, Ahmed R. Abu-Raghif, Hayder Adnan Fawzi. Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced ‎oxidative stress and inflammation in mice‎: ‎An in vivo study. Toxicology Reports 2024; 13 doi: 10.1016/j.toxrep.2024.101808
104
Alix Bruneau, Jana Hundertmark, Adrien Guillot, Frank Tacke. Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.725390
105
Abdulrahman Ismaiel, Mhd Bashir Almonajjed, Ahmed Abdelghafar, Mahdi Wardeh, Simona Grad, Teodora Surdea-Blaga, Stefan-Lucian Popa, Mohamed Ismaiel, Mohamed Abosheisha, Andreas-Friedrich Krauss, Paul Grama, Simona Bataga, Dan L. Dumitrascu. The Cost of the Cure: Antibiotic Exposure as a Risk Factor for Irritable Bowel Syndrome. Antibiotics 2026; 15(8) doi: 10.3390/antibiotics15080772
106
Moitreyee Chattopadhyay, Ansar Laskar, Sk Safiur Rahaman, Ananya Chanda. Gut Microbiota and their Impact on Disease Pathways and Interventions. 2025;  doi: 10.2174/9789815324549125010010
107
Mohamed Abouelkheir, Dalia A. Shabaan, Ahmed E. Taha. Rifaximin Protects Against Inflammation and Fibrosis in MASH: Any Role for Ethanol-Producing Bacteria?. Pathogens 2026; 15(2) doi: 10.3390/pathogens15020170
108
Audrey V Adler, Hailee R Ciccotti, Spencer J H Trivitt, Roland C J Watson, Mark S Riddle. What’s new in travellers’ diarrhoea: updates on epidemiology, diagnostics, treatment and long-term consequences. Journal of Travel Medicine 2022; 29(1) doi: 10.1093/jtm/taab099
109
Salma Sultan, Mohammed El-Mowafy, Abdelaziz Elgaml, Tamer A. E. Ahmed, Hebatoallah Hassan, Walid Mottawea. Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease. Frontiers in Physiology 2021; 12 doi: 10.3389/fphys.2021.715506
110
Jie-Yu Chuang. Stressor-Specific Microbiota Intervention. Frontiers in Nutrition 2022; 9 doi: 10.3389/fnut.2022.870665
111
Nimalan Arjun Jeganathan, Emily R Davenport, Gregory S Yochum, Walter A Koltun. The microbiome of diverticulitis. Current Opinion in Physiology 2021; 22 doi: 10.1016/j.cophys.2021.06.006
112
Haonan Li, Yujiao Xiang, Zemeng Zhu, Wei Wang, Zhijun Jiang, Mingyue Zhao, Shuyue Cheng, Fang Pan, Dexiang Liu, Roger C. M. Ho, Cyrus S. H. Ho. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. Journal of Neuroinflammation 2021; 18(1) doi: 10.1186/s12974-021-02303-y
113
Bálint Baráth, Dávid K. Jász, Tamara Horváth, Bence Baráth, Gergely Maróti, Gerda Strifler, Gabriella Varga, Lilla Sándor, Domonkos Perényi, Szabolcs Tallósy, Tibor Donka, Péter Jávor, Mihály Boros, Petra Hartmann. Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage. International Journal of Molecular Sciences 2022; 23(9) doi: 10.3390/ijms23095064
114
Hamed Memariani, Mojtaba Memariani. The Role of Gut Microbiota in Psoriasis: Current Knowledge and Emerging Therapeutic Interventions. International Journal of Enteric Pathogens 2024; 12(1) doi: 10.34172/ijep.5636
115
Fengqian Chen, Qi Liu. Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases. Advanced Drug Delivery Reviews 2022; 186 doi: 10.1016/j.addr.2022.114317
116
Kashif Mohd Siddiqui, Sumeet Attri, Massimo Orlando, Filippo Lelli, Valeria Maida, Dominique Damais-Thabut, Soe Thiha Maung. Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis. GastroHep 2022; 2022 doi: 10.1155/2022/1298703
117
Anna Pietrzak, Grażyna Rydzewska, Katarzyna Neubauer, Tomasz Banasiewicz, Wiesław Tarnowski. One-year cyclic therapy with rifaximin-α is effective in the treatment of SUDD (Symptomatic Uncomplicated Diverticular Disease) also in patients with a history of complicated diverticulitis. Polish Journal of Surgery 2023; 95(4) doi: 10.5604/01.3001.0053.8079
118
Hasnain N. Methiwala, Bhupesh Vaidya, Vamsi Krishna Addanki, Mahendra Bishnoi, Shyam Sunder Sharma, Kanthi Kiran Kondepudi. Gut microbiota in mental health and depression: role of pre/pro/synbiotics in their modulation. Food & Function 2021; 12(10) doi: 10.1039/D0FO02855J
119
Muhammad Faraz Raghib, Evanthia Bernitsas. From Animal Models to Clinical Trials: The Potential of Antimicrobials in Multiple Sclerosis Treatment. Biomedicines 2023; 11(11) doi: 10.3390/biomedicines11113069
120
Francesca Romana Ponziani, Alberto Nicoletti, Antonio Gasbarrini, Maurizio Pompili. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919848184
121
Xi-Chen Zhao, Xiao-Yun Sun, Bo Ju, Fan-Jun Meng, Hong-Guo Zhao. Acquired aplastic anemia: Is bystander insult to autologous hematopoiesis driven by immune surveillance against malignant cells?. World Journal of Stem Cells 2020; 12(11): 1429-1438 doi: 10.4252/wjsc.v12.i11.1429
122
Iain O’Neill. A Worldwide Perspective on Diagnosis and Management of Diverticular Disease: Understanding Similarities and Differences. EMJ Gastroenterology 2018;  doi: 10.33590/emjgastroenterol/10311869
123
Wanting Yang, Gaoyue Guo, Chao Sun. Therapeutic potential of rifaximin in liver diseases. Biomedicine & Pharmacotherapy 2024; 178 doi: 10.1016/j.biopha.2024.117283
124
Natalie Soliman, Caroline Kruithoff, Erin Marie San Valentin, Ahmed Gamal, Thomas S. McCormick, Mahmoud Ghannoum. Small Intestinal Bacterial and Fungal Overgrowth: Health Implications and Management Perspectives. Nutrients 2025; 17(8) doi: 10.3390/nu17081365
125
Xi-Chen Zhao, Li Zhao, Xiao-Yun Sun, Zeng-Shan Xu, Bo Ju, Fan-Jun Meng, Hong-Guo Zhao. Excellent response of severe aplastic anemia to treatment of gut inflammation: A case report and review of the literature. World Journal of Clinical Cases 2020; 8(2): 425-435 doi: 10.12998/wjcc.v8.i2.425
126
Sima Vadaei, Payam Gonbari Milani, Roya Abedi Soleimani, Azar Abedi Soleimani. Gut Microbiota: a Perspective for Postpartum Depression. Gastrointestinal Nursing 2023; 21(4) doi: 10.12968/gasn.2023.21.4.30
127
Antonio Tursi, Carmelo Scarpignato, Lisa L. Strate, Angel Lanas, Wolfgang Kruis, Adi Lahat, Silvio Danese. Colonic diverticular disease. Nature Reviews Disease Primers 2020; 6(1) doi: 10.1038/s41572-020-0153-5
128
Tilman Sauerbruch, Robert Schierwagen, Jonel Trebicka. Managing portal hypertension in patients with liver cirrhosis. F1000Research 2018; 7 doi: 10.12688/f1000research.13943.1
129
Vincenzo Di Leo, Patrick J. Gleeson, Fabio Sallustio, Carine Bounaix, Jennifer Da Silva, Gesualdo Loreto, Sanae Ben Mkaddem, Renato C. Monteiro. Rifaximin as a Potential Treatment for IgA Nephropathy in a Humanized Mice Model. Journal of Personalized Medicine 2021; 11(4) doi: 10.3390/jpm11040309
130
Kristýna Fiedorová, Hana Obručová, Hana Grombiříková, Martina Vaněrková, Eva Blaštíková, Soňa Štěpánková, Libuše Husová, Tomáš Freiberger. Longitudinal analysis of gut bacterial and fungal dynamics after solid organ transplantation. BMC Microbiology 2026; 26(1) doi: 10.1186/s12866-026-04753-x
131
Vincenzo Di Leo, Francesca Annese, Federica Papadia, Iris Cara, Marica Giliberti, Fabio Sallustio, Loreto Gesualdo. The Landscape of IgA Nephropathy Treatment Strategy: A Pharmacological Overview. Future Pharmacology 2023; 3(2) doi: 10.3390/futurepharmacol3020033
132
Moira B. Hilscher. A Helpful Bug in the System: Gut Microbes and Their Positive Impact on Portal Pressure Modulation. Cellular and Molecular Gastroenterology and Hepatology 2024; 18(6) doi: 10.1016/j.jcmgh.2024.101399
133
Carmelo Scarpignato, Giovanni Barbara, Angel Lanas, Lisa L. Strate. Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. Therapeutic Advances in Gastroenterology 2018; 11 doi: 10.1177/1756284818771305
134
Jae Gon Lee, Chang Soo Eun, Su Vin Jo, A-reum Lee, Chan Hyuk Park, Dong Soo Han, Hiroyasu Nakano. The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model. PLOS ONE 2019; 14(12) doi: 10.1371/journal.pone.0226907
135
Francesca Romana Ponziani, Barbara Funaro, Andrea Lupascu, Maria Elena Ainora, Matteo Garcovich, Gianluigi Caracciolo, Alessandro Quadarella, Antonio Nesci, Laura Riccardi, Antonio Gasbarrini, Maurizio Pompili, Maria Assunta Zocco. Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-51867-6
136
Taylor Hori, Yaw B. Owusu, Dianqing Sun. Encyclopedia of Infection and Immunity. 2022;  doi: 10.1016/B978-0-12-818731-9.00144-0
137
Xue Rui, Lihong Wu, Hang Ren, Shanshan Jia, Jinjin Dou, Xiwu Zhang. The gut-heart axis in heart failure: from bidirectional pathophysiological mechanisms to integrative therapeutic strategies. Frontiers in Microbiology 2026; 17 doi: 10.3389/fmicb.2026.1831648
138
N. V. Orlova, D. V. Lukanin. Diverticular disease of colon. Unresolved issues. Medical alphabet 2019; 2(27) doi: 10.33667/2078-5631-2019-2-27(402)-26-31
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.